← Back to Search

Exit Interview for Breast Cancer

Phase 2
Waitlist Available
Led By Mariana Chavez Mac Gregor, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion and average of 1 year.
Awards & highlights

Study Summary

This trial will help reduce the delay in chemotherapy initiation for breast cancer patients by providing them with individual support.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion and average of 1 year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion and average of 1 year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
General Self-Efficacy (GSE) Scale Questionnaires

Trial Design

2Treatment groups
Experimental Treatment
Group I: Group 2 (Control Group)Experimental Treatment2 Interventions
Participants will follow routine clinical care, where chemotherapy start date is determined by the provider and patient.
Group II: Group 1 (Investigational Group)Experimental Treatment2 Interventions
Participants will complete an in-depth patient needs checklist to identify patient-specific barriers that could lead to a delay with starting chemotherapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exit Interview
2022
N/A
~20

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,967 Previous Clinical Trials
1,804,802 Total Patients Enrolled
147 Trials studying Breast Cancer
63,286 Patients Enrolled for Breast Cancer
Mariana Chavez Mac Gregor, MDPrincipal InvestigatorM.D. Anderson Cancer Center

Media Library

Exit Interview Clinical Trial Eligibility Overview. Trial Name: NCT05488444 — Phase 2
Breast Cancer Research Study Groups: Group 1 (Investigational Group), Group 2 (Control Group)
Breast Cancer Clinical Trial 2023: Exit Interview Highlights & Side Effects. Trial Name: NCT05488444 — Phase 2
Exit Interview 2023 Treatment Timeline for Medical Study. Trial Name: NCT05488444 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care
2022. "A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05488444.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top